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Abstract
The formation of ovarian follicles is a finely tuned process that takes place within a narrow time-window in rodents. Multiple
factors and pathways have been proposed to contribute to the mechanisms triggering this process but the role of
endocrine factors, especially estrogens, remains elusive. It is currently hypothesized that removal from the maternal
hormonal environment permits follicle formation at birth. However, experimentally-induced maintenance of high 17b-
estradiol (E2) levels leads to subtle, distinct, immediate effects on follicle formation and oocyte survival depending on the
species and dose. In this study, we examined the immediate effects of neonatal E2 exposure from post-natal day (PND) 0 to
PND2 on the whole organism and on ovarian follicle formation in rats. Measurements of plasma E2, estrone and their sulfate
conjugates after E2 exposure showed that neonatal female rats rapidly acquire the capability to metabolize and clear
excessive E2 levels. Concomitant modifications to the mRNA content of genes encoding selected E2 metabolism enzymes in
the liver and the ovary in response to E2 exposure indicate that E2 may modify the neonatal maturation of these organs. In
the liver, E2 treatment was associated with lower acquisition of the capability to metabolize E2. In the ovary, E2 depleted the
oocyte pool in a dose dependent manner by PND3. In 10 mg/day E2-treated ovaries, apoptotic oocytes were observed in
newly formed follicles in addition to areas of ovarian cord remodeling. At PND6, follicles without any visible oocyte were
present and multi-oocyte follicles were not observed. Our study reveals a major species-difference. Indeed, neonatal
exposure to E2 depletes the oocyte pool in the rat ovary, whereas in the mouse it is well known to increase oocyte survival.
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Introduction
Mammalian birth is characterized by dramatic endocrine
changes and, in female rodents, this occurs concomitantly with
crucial morphogenetic processes in the ovaries. The formation of
ovarian follicles that occurs in the days following birth, will
determine the whole reproductive life of the female. Although a
fetus is likely to be exposed to high levels of steroids (in particular
progesterone and estradiol [1,2]), the maternal liver and excretory
organs manage their biotransformation and elimination. The fetus
is also protected by the placental barrier and by binding proteins.
Circulating steroids undergo a rapid decrease in the days following
birth and reach nadir at the end of the first week until the newborn
synthesizes its own steroids at the beginning of the infantile period
[1–6]. This sudden release from maternal hormonal impregnation
is associated with a rapid increase in the expression and activity of
enzymes involved in hormone metabolism and detoxification
machinery in the newborn liver [7,8]. As a consequence, the
newborn acquires the capability to metabolize a variety of
hormones and xenobiotics during the first week of life.
In the ovary, the formation of functional units (the follicles) from
the immature fetal ovarian cords also takes place within the three
days following birth [9,10]. Ovarian cords are composed of
clusters of germ cells progressing through the first prophase of
meiosis, surrounded by pregranulosa cells, and delineated by a
continuous basal membrane. They fragment thanks to the
deposition of a new basement membrane [11]. This fragmentation
is associated with the separation of oocytes, which remained
interconnected as nests or cysts during synchronous mitosis [9,10],
and with a massive wave of degeneration specifically targeting
oocytes resulting from both apoptotic and autophagic mechanisms
[12–15]. A number of factors, mechanisms and pathways have
been suggested to be involved in follicle formation. These include
the endogenous meiosis clock, central signals and neurotrophic
factor signaling, growth factor signaling (especially those of the
transforming growth factor family) and transcription factors (for
review, [10]). In addition, several studies have highlighted
endocrine factors such as progesterone and 17b-estradiol (E2) as
candidate actors of follicle histogenesis in several specie from mice,
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rats to cattle and primates [4,16–18]. It is currently hypothesized
that the decrease in maternal E2 impregnation that follows birth
permits oocyte cyst breakdown, and consequently, follicle forma-
tion. Therefore, maintenance of high E2 levels or exposure to E2-
mimicking molecules may result in inhibition of oocyte cyst
breakdown. However, experimentally-induced high neonatal E2
levels have subtly-diverging immediate effects depending on the
species (and even strains) in terms of oocyte survival and ovarian
cord fragmentation, i.e. follicle formation. High post-natal E2
levels increase oocyte survival but inhibit follicle formation in mice
[4,18]. However, they promote both follicle formation and oocyte
survival in the hamster [19,20]. In the baboon, maintenance of
maternal E2 levels are required for follicle formation since a
treatment with an aromatase inhibitor leads to a sharp inhibition
of the process [21]. In the rat, E2 moderately inhibits follicle
assembly but increases primordial-to-primary follicle transition
in vitro and leads to hypoplastic ovaries from post-natal day (PND)
4 onward [16,22]. A typical feature of neonatal exposure to E2 or
xeno-estrogens such as diethylstilbestrol (DES), bisphenol A (BPA)
and genistein (GEN) is a high incidence of multi-oocyte follicles
(MOFs) in peripubertal mice and rats [18,23–28]. Although these
MOFs are thought to arise from reduced oocyte cysts breakdown,
oocyte apoptosis and/or basement membrane neosynthesis and
deposition, the fine etiology of this morphogenetic abnormality
and the role of estrogenic compounds are still obscure.
Increasing concerns of xeno-estrogens impact on health have
led to experimental studies using compounds displaying various
estrogenic activities (DES, BPA, GEN …). The use of E2 or
estradiol-like molecules with distinct kinetic properties (including
ethinyl estradiol, estradiol-benzoate, estradiol–valerate and estra-
diol-cypionate) as reference molecules has increased the complex-
ity of this issue. Although E2 is widely used as a reference molecule
in comparisons with xeno-estrogens, its own mechanism of action
is not completely understood. In addition, due to the availability of
transgenic mice, many studies addressing the effects of a neonatal
exposure to E2 and xeno-estrogens on follicle formation have been
carried out using mice. Although the rat has often been the model
of choice to study molecules affecting the sexual differentiation of
the central nervous system [29,30], the direct effects of neonatal
E2 exposure to the ovary remains unclear in this species.
As a consequence, the aim of this study was to better clarify the
immediate adverse effects of E2 on the ovary in the rat. To that
purpose, we injected newborn pups with E2 during the short time
window corresponding to follicle formation. As a prerequisite for
an acute evaluation of E2 exposure and in an attempt to define
effective doses, we examined dose-effects using doses between
10 mg/day/animal and 0.01 mg/day/animal and compared the
dynamics of the resulting plasma E2 in the pups. To gain insights
into the fate of E2, we also evaluated dynamics of circulating
metabolites and the effects of E2 treatment on the expression of
the enzymes of the detoxification machinery in the newborn liver.
In the ovary, we searched for detoxification capabilities and
evaluated the impact of E2 exposure on: i) these possible local




The animal facility is licensed by the French Ministry of
Agriculture (agreement # C 35-238-19). All the experimental
procedures followed ethical principles according to the NIH Guide
for Care and Use of the Laboratory Animals and were approved
by the Rennes Animal Experimentation Ethics Committee (#R-
2012-CCh-01).
Animal Handling and Treatments
Adult Sprague-Dawley rats were conventionally housed at
adequate temperature (2265uC) and humidity (around 55%) with
12:12 h light/dark cycles and free access to food and tap water.
Their food contained soy (Special Diets Services, Witham,
England). Females were mated overnight with males. The
following day was considered to be embryonic day 0 (e0).
Pregnant females were isolated three days before birth, which
generally occurs at e22.5. Newborn females received a subcuta-
neous injection of 17b-estradiol or corn oil (vehicle–negative
control) (Sigma Aldrich) within a few hours after birth (PND0) and
on two subsequent days (PND1 and 2). Animals were divided in
five groups: one group received the negative control and four
experimental groups received 0.01, 0.1, 1 or 10 mg/day of 17b-
estradiol.
Organs and Plasma Collection
Animals were killed by decapitation in the morning of PND0, 1,
2, 3 or 6. Trunk blood was collected into heparinized tubes and
centrifuged, and plasma was kept frozen (220uC) until steroid
hormone assay. Ovaries were collected at each age, separated
from the ovarian capsule and fixed overnight in Bouin’s solution
for immunohistochemistry or in 2% paraformaldehyde-PBS
(pH 7.2) for 1 h at 4uC for in situ hybridization. Livers and
ovaries were removed and snap frozen for RNA extraction.
Hormone Measurements
Serum samples from two or three animals were pooled and
randomized before assaying. Estrone (E1), estradiol (E2), estrone-
sulfate (E1-S) and estradiol-sulfate (E2-S) were assayed in two steps
using mass spectrometry coupled with gas chromatography
[31,32]. Sera were overloaded with deuterated steroid internal
standards (CDN isotopes Inc., Canada) and extracted with 1-
chlorobutane. The organic extracts were purified on conditioned
LC-Si SPE columns (Varian, Les Ulis, France). E1 and E2 were
derivatized with pentafluorobenzoyl chloride (103772-1G, Al-
drich, Steinheim, Germany). The final extracts were reconstituted
in isooctane and transferred into conical vials for injection into the
GC system (6890N, Agilent Technologies, Massy, France) using
50% phenylmethylpolysiloxane VF-17MS capillary columns
(20 m60.15 mm, internal diameter, 0.15 mm film thickness)
(Varian, Les Ulis, France). An HP5973 (Agilent Technologies,
Massy, France) quadrupole mass spectrometer equipped with a
chemical ionization source and operating in single ion monitoring
(SIM) mode was used for detection. E1-S and E2-S retained in the
aqueous phase of the extraction were measured after acid
solvolysis as E1 and E2, respectively [33]. Accuracy, target ions,
corresponding deuterated internal control, range of detection, low
limit of quantification (LLOQ), and intra & inter assay CVs of the
quality control serums are reported in table S1.
In situ Hybridization and Coupled Immunofluorescence
Fixed ovaries were cryoprotected in 20% (wt/vol) sucrose in
PBS for 1 h, embedded in Tissue-Tek OCT compound (Miles,
Inc., Elkhart, IN), cut into 8 mm-thick sections, mounted onto 3-
aminopropyltriethoxysilane-treated glass slides (Sigma-Aldrich
Corp., St. Louis, MO) and stored at 220uC. The cDNAs used
for synthesis of the different riboprobes were obtained by RT-PCR
and subcloned into pGEMTeasy (Promega). The nucleotide
sequences were verified by sequencing. Primers and product
Neonatal Estradiol Exposure Effects in the Rat
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lengths are given in Table 1. Riboprobes were generated by
transcription with digoxigenin-labeled deoxy-UTP and the
appropriate SP6 or T7 RNA polymerase (Roche). In situ
hybridization on frozen sections was carried out as previously
described [5]. Detection of apoptotic cells was performed on
sections previously treated for Ybx2 in situ hybridization using the
in situ cell death detection kit, Fluorescein (terminal deoxynucleo-
tidyltransferase-mediated deoxy-uridine 59-triphosphate-fluoresce-
in nick end labeling (TUNEL), Roche). After PBS washing,
sections were incubated with the TUNEL reaction mixture
containing terminal transferase for 1 h at 37uC. For double
labeling of sections (if appropriate after detection of Ybx2 or Gper
mRNA by in situ hybridization), sections were rinsed in PBS and
incubated overnight at 4uC with Esr2 (Biogenex, AR385-5R,
RTU), fibronectin (Sigma Aldrich, F3648, 1:100) or Ybx2 (Santa
Cruz Biotechnologies, Inc. Santa Cruz, CA, sc-21316, 1:200)
antibodies. An antigen retrieval procedure was necessary before
Esr2 antibody incubation (10 mM citrate buffer, pH 6, at 80uC for
45 min). After washing, sections were incubated with secondary
488- or 594-Alexa anti-rabbit (Esr2, fibronectin) or anti-goat
(Ybx2) antibodies (IgG Alexa antibodies, Invitrogen, 1:500). The
second primary antibody was incubated overnight with the
sections at 4uC, and the second antigen/antibody complex was
then reacted with the appropriate secondary antibody. For
TUNEL associated with fibronectin detection, the TUNEL
reaction was performed as described and followed by fibronectin
labeling. Fluorochrome-labeled sections were mounted in Vecta-
shieldH containing the DNA stain DAPI (Vector Laboratories),
and analyzed with a Zeiss Axio Imager M1 fluorescence
microscope connected to a digital camera (Carl Zeiss New York,
NY).
Stereological Counts
For oocyte counts, PND0, 1, 2 and 3 ovaries were fixed with
Bouin’s solution, dehydrated and paraffin embedded according to
standard procedures. One out of every five 5 mm sections were
mounted with albumin on TESPA-treated glass slides. After
dewaxing and rehydration, an antigen retrieval procedure was
performed with citrate buffer 10 mM pH 6 at 80uC for 45 min.
Unspecific sites were saturated with 10% Bovine Serum Albumin
(BSA)-PBS and the sections were incubated overnight at 4uC with
the primary antibody (Gena, clone TRA98, Clinisciences, 1:100
diluted in Dako antibody diluent). After washes in PBS, sections
were reacted with a biotinylated secondary antibody (Sigma
Aldrich; 1:500 in PBS) and incubated for 4h at room temperature.
An avidin-biotin complex linked to a peroxidase (Vectastain Elite
ABC kit, Vector Labs) was used to bind to diaminobenzidine, a
peroxidase substrate (Sigma Aldrich). Sections were counter-
stained with Masson’s Hemalun, dehydrated and mounted in
Eukitt (Kindler GmbH). For total oocyte counts, Gena/TRA98-
positive cells were counted by using the Computer-Assisted
Stereology Toolbox (CAST) Grid System (Olympus, Copenhagen,
Denmark) on a light microscope (Olympus BX S1). At first, we
delineated the ovarian borders at low magnification. The ovarian
volume was deducted by multiplying the sum of the surfaces of
each section by the thickness of the sections (5 mm) and another
time by 5 because measurement was done every fifth sections.
Then, we counted the immunopositive cells using the oocyte
nucleus as a marker at 100X using a high-numerical-aperture
objective lens on each section. All oocytes were added together to
reflect an estimation of the total oocyte number per ovary. For
dying oocyte counts, apoptotic cells were detected by the TUNEL
technique using the Apoptag cell kit (Millipore, S1700) according
to manufacturer’s instructions. TUNEL-positive oocytes were
counted in every fifth section and added together to give the total
apoptotic oocytes per ovary. Stained sections were examined
under a light microscope (Olympus BX51).
RNA Extraction and Polymerase Chain Reaction (PCR)
RNA extractions from ovaries and livers were carried out with a
Nucleospin XS kit (Macherey Nagel; 740902) according to
manufacturer’s instructions. Total RNAs (250 ng) were reverse
transcribed with random primers and Moloney Murine Leukemia
Virus Reverse Transcriptase (Invitrogen). Conventional PCR was
performed using Taq polymerase (Qiagen) in a Peltier thermo-
cycler (MJ Research, Bio-Rad DNA engine) using the primers
listed in Table 1. PCR consisted of an initial denaturation at 94uC
for 3 min, 35 (or 42 in the case of Sult1e1) cycles of 94uC for 30 s,
1 min of annealing, 72uC for 30 s and a 10 min 72uC final
extension. Quantitative PCR was performed using the GoTaq
Master mix (Promega) according to manufacturer’s instructions
with 0.5 ml cDNA template in an Applied Biosystems 7500 Real-
Time PCR system. The following amplification program was used:
a 2 min holding stage at 50uC, initial denaturation of 10 min at
95uC, 40 cycles of 1 sec amplification at 95uC and 1 min at 60uC
for annealing and extension. Dissociation curves were produced
using a thermal melting profile performed after the last PCR cycle.
To avoid amplification of contaminating genomic DNA, primer
pairs were selected on either side of an intron. Snx17 mRNA was
used as an internal control for normalization. Results were
expressed by DDCT method as n-fold differences in target gene
expression, relative to the reference gene and calibrator sample
which is constituted of an equal mixture of all the samples tested
specifically in each tested organ.
Data Analysis
Microarray data analysis was carried out on datasets from
Kezele et al, [34], GSE 9300 (GSM237013-237016) using the
Annotation, Mapping, Expression and Network (AMEN) analysis
software [35]. GeneChip data were normalized using the Robust
Multi-Array Average (RMA) method and the resulting expression
values for ovary replicates at PND0 and PND4 were averaged.
Probe sets yielding a signal higher than the detection threshold
(median of the normalized dataset, cutoff 7.47), and a fold-change
$1.5 between PND0 and PND4 averaged ovary samples, were
selected. A Linear Model for Microarray Data (LIMMA) statistical
test (F-value adjusted with the False Discovery Rate method:
p#0.05) was used to identify probe sets with significantly different
expression. For further classification, we divided the selected probe
sets into groups being significantly decreased or increased in
PND4 ovary samples as compared to PND0. We restricted our
subsequent analysis to probe sets corresponding to genes
associated with the ‘‘steroid metabolic process’’ Gene Ontology
annotation term (GO:0008202).
Statistical Analysis
Quantitative PCR data and cell counts are presented as mean6
SEM. Blood and ovaries for quantitative PCR from different
animals were pooled to form one sample and several pools from
different litters were used for a given treatment and time point.
The sizes of the pools are given in each figure legend. For oocyte
counts, 4–13 ovaries were used, as specified for each parameter in
the corresponding figure legend. An analysis of the variance (one-
way or two-ways ANOVA) followed by the appropriate post-hoc
test was used to compare differences between groups, as specified
in each figure legend. Significance was accepted at a confidence
level of p#0.05. Statistical analyses were performed using the
Neonatal Estradiol Exposure Effects in the Rat
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SigmaStat 2.0 software package (Systat Software Inc, San Jose,
CA).
Results
Response of the Whole Organism to E2 Exposure
Besides its biological activity involving by binding to receptors
and subsequent transcriptomic activity, E2 is transformed into
several possible metabolites before excretion (Fig. 1A). To monitor
the dynamics of plasma E2 levels after E2 treatment in comparison
to physiological levels, we measured E2 levels in rat neonates at
PND0 (before injections) and 16 h after each injection on days
PND1 to PND3 and PND6 (Fig. 1B). The mean E2 levels
significantly decreased after birth in control females and drastically
dropped at PND6. All treated groups followed the same trend,
except the 0.01 mg group which did not differ from controls. E2
plasma levels increased at PND1 following the first injection of E2
(statistically significant in only the 10 mg/d-treated group), but
significantly decreased until PND3 in spite of repeated injections.
Plasma E2 levels of the 10 mg/d-treated group did not return to
baseline at PND3 but were the same as control levels from PND6
onwards.
To explore the fate of E2 in the females, we quantified the
presence of several major E2 metabolites (estradiol-sulfate (E2-S),
estrone (E1), and estrone-sulfate (E1-S)), at the same time points
(Fig. 1B–E). Estriol (E3), another natural E2 metabolite, was also
assayed but all the samples displayed concentrations below the
detection limit (10 pg/ml). In contrast to E2, E2-S remained
constant in all samples, irrespective of the huge raise in E2 levels in
the 10 mg/d group (Fig. 1C). Time, but not treatment, had a
significant effect on E2-S level (P,0.001). E1 profiles were highly
similar to those of E2 in accordance with the injected dose
(Fig. 1D). The higher E1 levels at PND1 were statistically
significant in the 10 mg/d and 1 mg/d groups. Similar to E2, E1
levels dramatically dropped at PND6 with time and treatment
having independent effects. E1-S peaked at PND3, and this
increase was significant in the 10 mg/d and 1 mg/d groups. In all
groups, plasma E1-S levels decreased between PND3 to PND6
(Fig. 1E). The two-way analysis of variance revealed that the
variation of all metabolite levels was statistically correlated with
time, independently of treatment. The dose of injected E2
significantly affected the mean values of all metabolites except
E2-S. The multiple comparison procedure identified the E2
10 mg/d group as different.
The increase in E1 levels after E2 injections suggested a
metabolic conversion between those two forms. We therefore
investigated variation in the expression of Hsd17b2, and of several
phase-I and phase-II enzymes involved in hepatic detoxification of
estrogens (Ugt1a1, Cyp1b1, Cyp2b1/2 and Gsta2), in response to
10 mg/d E2 by quantitative PCR in the liver (Fig. 1F–J). mRNA
levels of Hsd17b2 and Cyp2b1/2 increased from PND0 to PND1 in
the control group but there was no variation in the E2-treated
Table 1. Primers used for qPCR and in situ hybridization (*).
Gene Upstream primer Downstream primer Product length (bp) Annealing TuC
Bax CTAGCAAACTGGTGCTCAAGG GGAGGAAGTCCAGTGTCCAG 84 60
Bcl2 AACATCGCTCTGTGGATGACT ACAGCCAGGAGAAATCAAACA 133 60
Cyp1b1 GCAGCCGCCTTCCTGGTAGC CCACGCGCCCTGTCCCTACT 116 60
Cyp2b1/2 ATGTTTGGTGGAGGAACTGC CTGGCGGTCTGTGTAGTCAA 130 63
Eif4e AGCAATATGGACGACTGAATGTGA TGTCTGCGTGGGACTGATAACC 119 60
Esr1 GATCAAGTTCACCTTCTGGA AGCAAGTTAGGAGCAAACAG 107 60
Esr1 * CTACAGGTCCAATTCTGACA TGGAGACATGTAGTCATTATG 220 58
Esr2 GAAGCTGAACCACCCAATGT CAGTCCCACCATTAGCACCT 210 60
Esr2 * ACGGTGGGCATGCACCCC GCCAATCATGTGCACCAG 201 58
Figla ATGGACACGTCGTCGCCTGC TGGCCACCATACGCCCAAGG 524 60
Foxa3 ATGCTGGGCTCAGTGAAGAT GGGAGAGCTAAGAGGGTTCAA 147 60
Gper TCTACCTAGGTCCCGTGTGG AAGCTCATCCAGGTGAGGAA 418 60
Gper * TCTACCTAGGTCCCGTGTGG AAGCTCATCCAGGTGAGGAA 418 58
Gsta2 GGCAAAAGACAGGACCAAAA GGCTGCAGGAACTTCTTCAC 231 62
Gstm5 GGTTTGCAGGAGAAAAGCTG TGATTGGCATCTTGAAGCAG 186 62
Gstp1 GGGCATCTGAAACCTTTTGA GAGCCACATAGGCAGAGAGC 175 63
Hnrnpk TGCTGATGAAACTTGGGACTCTG CGAATTTGTTTAATCCGCTGACC 222 60
Hsd17b2 GACAAAGGACTGTGGGCTGT AACACCTTGGTGACCTCGAC 137 60
Nobox GAAGACATGGGACCTCAGGA GCCGAAAGGAAATGAAAACA 192 60
Nr1i2 GACGGCAGCATCTGGAACTAC TGATGACGCCCTTGAACATG 112 60
Rbp4 GGACGAGTCCGTCTTCTGAG AAAGGAGGCTACACCCCAGT 114 60
Scp1 AGCTTTTGGGAGAGGTTGAGAA TCAGCTATTTTATGTTGGCATCGT 97 62
Snx17 CCTCTACCCAAGAGGAGATTTATACAA CCAAGAGGGAACAGAACAAGT 100 60
Sult1e1 GTGGAAAAATGCAAGGAGGA GCTTAGCTGGCAGGTGAGTT 139 58
Ugt1a1 ACACCGGAACTAGACCATCG TTGGAACCCCATTGCATATT 153 62
Ybx2 * CACCTCCCTTCTTCTATCGA GGTGATGCCTCTGAACAATA 637 58
doi:10.1371/journal.pone.0082175.t001
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Figure 1. Plasma and hepatic reaction to acute estrogen exposure. A. Representative scheme of E2 biological activity and detoxification
pathways. E2 can go through oxidative metabolism and be converted in E1 by 17bHsd2 or in hydroxyl-metabolites by enzymes of the Cyp family.
Then it can be methylated by COMT, reduced by P450 reductase (resulting in DNA damage) or excreted after conjugative metabolism by GST. E2 can
Neonatal Estradiol Exposure Effects in the Rat
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group (Fig. 1F, I). Ugt1a1 levels did not vary significantly with age
or treatment (Fig. 1G). The levels of Cyp1b1 mRNA (Fig. 1H) were
lower at PND1 than at PND0 and treatment had no effect. In
contrast, the levels of Gsta2 mRNA were higher at PND1 than at
PND0 in 10 mg/d-treated and control animals (Fig. 1J).
Ovarian Estrogen Receptivity in Response to E2 Exposure
Regulation of expression of the well known-nuclear estrogen
receptors, i.e. Esr1, Esr2, of the membranous estrogen receptor Gper
and of the nuclear receptor Nr1i2, which can bind estrogens and
whose expression is regulated at birth in mouse ovary [36,37] was
assessed around the time of treatment by quantitative PCR
(Fig. 2A–D). The expression of Esr1 mRNA significantly decreased
between e18.5 and PND12 (Fig. 2A), while expression of Esr2
mRNA was low at e18.5 and significantly increased from birth to
PND12 (Fig. 2B). Gper and Nr1i2 mRNA had similar age-
associated expression profiles (Fig. 2C–D).
We investigated which ovarian cell types expressed estrogen
receptors around the time of treatment and in later development
in ovarian sections using in situ hybridization (Fig. 2 E–P, M) and
immunofluorescence (Fig. 2 M–O). From PND1 on, we observed a
strong Esr1 mRNA signal in the epithelium of the differentiating
oviduct (Ovd in Fig. 2E) and a close-to background signal in the
ovary (Fig. 2E, H and Figure S1). Esr2 mRNA was expressed in
the epithelium of the differentiating oviduct as well as in the ovary
(Fig. 2F) and its expression increased in granulosa cells with follicle
growth at PND6 (Fig. 2 F, I and K). Gper mRNA expression
pattern was very similar to that of Esr2 (Fig. 2 G, J and L). The
comparison of Gper mRNA and Esr2 protein labeling with the
oocyte marker Ybx2 showed that oocytes expressed both receptors
(Fig. 2 L–O). These data suggest that some Esr1, and to a greater
extent Esr2 and Gper, were expressed in the oocytes and (pre-
)granulosa cells at the time of estrogen injections.
Since estrogen receptors themselves have been described as
direct target of estrogens, we measured the profile of expression of
their transcripts in response to a 10 mg–E2 exposure (Fig. 2 N–Q).
Quantitative PCR at PND0, between 2 and 4 h after injection,
and at PND1 was carried out to investigate the early transcrip-
tomic response of the ovary. Esr1 had a stable expression between
PND0 and PND1 and treatment did not affect its expression
(Fig. 2N). Similarly, Esr2 had a stable expression in the control
group between PND0 and PND1 and, although E2 treatment
tended to increase the expression between PND0 and PND1, this
did not reach statistical significance (Fig. 2O). Expression levels of
Gper significantly increased between PND0 and PND1 in the
control group but remained unchanged in the E2-treated group
(Fig. 2P). A similar post-natal increase in Nr1i2 mRNA expression
was found in control ovaries but not observed in E2-treated
ovaries (Fig. 2Q).
Modifications of Ovarian Metabolic Capabilities in
Response to E2
To get insights into the expression of enzymes of the E2
metabolic pathway in the post-natal ovary, we explored already
published transcriptomic profiles of PND0 compared to PND4 rat
ovaries [34]. We restricted our analysis to the 227 probe sets
(transcripts) associated with the GO term annotation ‘‘steroid
metabolic process’’ (GO:0008202). Out of the 133 probe sets with
detectable intensity signals in either PND0 or PND4, 114
transcripts did not display differential expression. However, we
found 12 to be associated with a significantly increased expression
pattern from PND0 to PND 4, and four to be associated with a
significantly reduced expression pattern (Fig. 3A). Enzymes
involved in E2 biosynthesis increased after birth (statistically
significant differences in mRNA expression for Star and Hsd3b1,
but not significant for Cyp17a1 and Hsd17b1). This may well
correlate with the very first steps of theca-interstitial tissue
differentiation. In contrast, mRNAs encoding enzymes involved
in E2 transformation such as Sult1a1 and, to a lesser extent,
Hsd17b2, and Cyp1b1 decreased in prevalence between PND0 and
PND4 (Fig. 3A). Because the microarrays used in this study
covered approximately half of the known protein-coding genes,
data were partial. We thus selected enzymes of each branch of E2
detoxification pathway to compare by quantitative PCR their
expression in PND0 and PND1 neonatal and adult ovaries as well
as in PND0 livers (Fig. 3B). The mRNA levels of Hsd17b2, Cyp1b1,
Cyp2b1/2, Gsta2 and Gstp1 were globally constant over time. By
contrast, Sult1e1, Ugt1a1 and Gstm5 were preferentially expressed
in the neonatal ovary and merely absent in the adult organ. Of
note, Ugt1a1 and Gstm5 were preferentially expressed in the ovary
while Cyp2b1/2 was preferentially expressed in the liver, thus
highlighting different pathways of detoxification in each organ.
Altogether, these results suggest that the ovary possesses the
machinery to locally metabolize E2.
We used quantitative PCR to investigate variation in the
expression of selected estrogen metabolism enzymes in response to
E2 exposure (Fig. 3 C–F). The expression of Hsd17b2 was similar
in the control and treated groups at PND0. Whereas it remained
constant at PND1 in the control group, E2 treatment induced a
significant increase in expression in the treated group (Fig. 3C).
Cyp1b1 mRNA levels did not vary 2 h after the E2 injection
(Fig. 3D). However, whereas Cyp1b1 mRNA levels increased
significantly between PND0 and PND1 in the control group, they
remained unchanged in the treated group (Fig. 3D). The
expression of Cyp2b1/2, which was slightly greater in the control
group than in the treated group at PND0, dramatically increased
between PND0 and PND1 in control group but did not
significantly change in the E2-treated group (Fig. 3E). Expression
of Gsta2 did not vary in the control group, but significantly
increased in the treated group between PND0 and PND1 (Fig. 3F).
Ugt1a1 mRNA profile was not modified with either time or
treatment (Fig. 3G). Rbp4, which has previously been shown to be
also be directly sulfo-conjugated by SULT or gluco-conjugated by UGT, and excreted. B–E. Plasma estradiol (B) and derivatives E2-sulfate (E2-S; C),
estrone (D) and estrone-sulfate (E1-S; E) were measured by GC/MS from the day of birth (P0) to PND6 (P6). Each point represents the mean 6 SEM of
at least four pools of two animals each. A two-way ANOVA indicated that there was a significantly different profile for the 10 mg/d E2 treatment than
for all other treated or control groups (p,0.001), E1 (p,0.001), E1-S (p = 0.002). Hormonal levels varied according to time, independent of treatment,
for each metabolite tested: E1 (p,0.001), E2 (p,0.001), E1-S (p,0.001) and E2-S (p,0.001) (n = 4–5 pools of 3 to 4 animals at PND0, 4–5 pools of 2–4
animals at PND1, 4 pools of 2–3 animals at PND2, 4 pools of 2 animals at PND3 and 8 animals at PND6). F–J. Quantitative RT-PCR for Hsd17b2 (F),
Ugt1a1 (G), Cyp1b1 (H), Cyp2b1/2 (I) and Gsta2 (J) using liver samples of controls (white bars) and animals treated with 10 mg E2 at PND0 and PND1
(black bars) shows E2 impairment on post-natal Hsd17b2, Cyp2b1/2 and Gsta2 expression dynamics. Each bar represents mean 6 SEM of the fold-
change in target gene expression relative to a reference gene Snx17 and calibrator sample. Each point represents mRNA from 3 pools of ovaries from
3 animals. *p,0.05 (two-way ANOVA, followed by Tukey test). a shows an increase from PND0, b shows a decrease from PND1, c shows a decrease
from PND3 and * shows a difference from the age-matched control group.
doi:10.1371/journal.pone.0082175.g001
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Figure 2. Perinatal ovarian receptivity to estrogens. A–D: Quantitative RT-PCR for Esr1 (A), Esr2 (B), Gper (C) and Nr1i2 (D) performed on
control ovaries at e18.5, day of birth (PND0) and PND12. Each point is constituted by three pools of at least four animals. Data points represent the
mean 6 SEM of the fold-change in target gene expression relative to a Snx17 reference gene and calibrator sample. Each point represents mRNA
from 3 pools of ovaries from 3 animals. *p,0.05 (ANOVA, followed by PLSD test). x shows a statistically significant difference from e18.5 and y shows
a statistically significant difference from PND0. E–P. In situ hybridizations for Esr1 (E, H), Esr2 (F, I, K), and Gper (G, J, L) in PND1 (E–G), PND6 (H-K) and
PND2 (L-P) control ovaries show lower Esr1 expression in the ovary than in the oviduct epithelium (Ovd), higher expression of Esr2 in granulosa cells
with follicle growth, and expression of Gper in the oocytes and granulosa cells. Inset in F shows a higher magnification of a group of follicles boxed in
F. K shows a higher magnification of a primary (Iary and a secondary (IIary) follicles boxed in I. Inset in G shows another section of the ovary
containing the oviduct. A comparison of Gper mRNA profile by in situ hybridization (L) with Esr2 (N, red) and Ybx2 (M, cytoplasmic, green) (and
merged pictures O) by immunofluorescence revealed co-expression of both receptors in oocytes at the time of treatment. P shows hybridization with
Gper sense probe. Scale bar: 100 mm except in insert in F and K (50 mm). Q-T. Quantitative RT-PCR for Esr1 (Q), Esr2 (R), Gper (S) and Nr1i2 (T) using
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a target of E2 in the fetal and juvenile rat ovaries [38], followed the
same trend as Cyp1b1 and Cyp2b1/2, albeit not significantly
(Fig. 3H).
Estrogen Dose-dependent Depletion of Oocyte Pool
Repeated 10 mg E2 treatment is known to effect the volume of
infantile [22] and pre-pubertal ovaries [39]. Since sections of
PND3 ovaries of the 10 mg/d group were smallest compared to
control ones at the histological level (Fig. 4A–C), we performed
stereological measurements of ovarian volumes for each dose
group (10, 1, 0.1 and 0.01 mg/d) after the end of the treatment at
PND3 (Fig. 4D). Ovarian volume followed a dose-dependent
decrease after E2 treatment but this was only statistically
significant for the 10 mg/d dose (Fig. 4D). Because this modifica-
tion was rapid, we chose to evaluate the total number of oocytes
instead of categorizing naked/primordial/primary follicles by
morphological criteria using oocyte nucleus labeling with GENA
[40] (Fig. 4E). Oocyte population decreased as a function of the
dose of injected E2: at doses of 1 mg/d and above, the population
size was significantly different to that of control individuals. These
data suggested that neonatal E2 supplementation depletes the
oocyte pool in female rats. We used the 10 mg dose for further
investigations as this dose had effective effects on both ovarian
volume and oocyte number.
We analyzed the time-course of oocyte depletion after a 10 mg/
d E2 treatment (Fig. 5A). Oocyte numbers decreased with a similar
slope between PND0 and PND2 in control and treated groups and
oocyte depletion extended for one more day in E2-treated females
(Fig. 5A). Since oocyte apoptosis is a physiological process that
characterizes follicle formation [12,14], we quantified apoptotic
oocytes after TUNEL assays between PND0 and PND2 in control
and E2-treated females (Fig. 5B). Both groups of females displayed
a similar post-natal decline in apoptotic oocyte number from
PND0 to PND2 and we could not detect any difference between
control and treated ovaries (Fig. 5B). In agreement, the mRNA
levels of the pro-apoptotic Bax gene (measured by quantitative
PCR) were stable in both control and treated ovaries between
PND0 and PND2 (Fig. 5C). By contrast, the mRNA levels of the
anti-apoptotic Bcl2 gene were steady stable in control ovaries while
lower to control ones 4 h after the first injection and then
increasing in E2-treated ovaries (Fig. 5D).
We investigated the expression of genes proposed to be involved
in follicle formation (Figla, Hnrnpk, Foxo3a and Nobox) and meiosis
progression (Eif4e, Scp1) [41–47]. To detect early changes triggered
by the E2 treatment, quantitative PCR were performed before a
decrease in oocyte number was detected (at PND0, PND1 and
PND2). E2 treatment only affected the profile of Nobox expression
at PND2 (Fig. 5E–J): Nobox mRNA expression increased between
PND1 and PND2 in control ovaries but not in E2-treated ones.
This suggested that, apart from Nobox, genes classically involved in
follicle formation may not have a role in E2-induced oocyte
depletion.
Abnormalities of Follicle Formation in Response to E2
Exposure
The wave of physiological oocyte programmed cell death
progresses from core areas to the periphery of the ovary in rodents
[48]. Degenerating oocytes are located in areas of new basement
membrane deposition which delineate the emerging follicular units
[11]. We investigated the topographical pattern of oocyte
degeneration by comparing TUNEL-positive cells and fibronec-
tin-labeled extra-cellular matrix at PND1 (Fig. 6A–D). Whereas
typical apoptotic oocytes were found close to basal membrane
remodeling in both control and E2-treated ovaries, numerous
degenerating oocytes, already enclosed in follicles, were observed
in the core of the E2-treated ovaries (Fig. 6D).
Because MOFs are a hallmark of neonatal estrogenization, we
investigated cord fragmentation by analyzing fibronectin-labeled
basal membrane deposition around newly formed follicular units
(Fig. 6 E–H). Ovarian cord fragmentation was nearly complete in
control animals at PND3 (Fig. 6E) but follicle formation
anomalies, such as epithelial structures devoid of oocyte and
incomplete cord fragmentation, were observed in 10 mg-treated
animals (Fig. 6F). At PND6, an age at which follicle formation is
known to be completed (Fig. 6G), many abnormalities (such as
follicular units devoid of oocytes) remained in E2-treated ovaries
(Fig. 6H).
Discussion
Our results provide direct evidence that the newborn female rat
rapidly acquires the capability to partially protect itself against
repeated E2 injections by decreasing E2 in the plasma. This is
associated with a change in the expression profiles of several
hepatic detoxification enzymes involved in its own metabolism.
Interestingly, the ovary itself expresses enzymes for E2 metabolism
and modifies their expression in response to E2. We show that
neonatal E2 exposure can directly affect oocyte survival in a dose-
dependent manner in the rat. Oocyte depletion is time-dependent
for the highest dose tested and affects already formed follicles in
addition to areas of ovarian cord remodeling. The data highlights
a dramatic species difference as experimentally-increased E2 levels
promote oocyte survival in the mouse.
Whole Organism Response to E2
In our control female pups, E2 levels decreased from 90+/
23 pg/mL at PND0 to 24+/211 pg/mL at PND3 and fell to 2+/
22 pg/mL at PND6. The 0.01, 0.1, 1 and 10 mg/d doses raised
the levels up to 80+/217, 233+/2199, 618+/234 and 3685+/
2968 pg/mL at PND1, respectively. By comparison, mean E2
levels in ovarian venous blood during pregnancy have been
described to plateau at levels between 120+/219 to 199+/
255 pg/mL between e3 and e17, which are close to estrus levels
(161+/228 pg/mL), then raise up to 445+/2115 pg/mL at e21,
348+/274 at e22, and peak at 628+/2210 pg/mL at parturition
[49]. Studies on xeno-estrogen effects on the ovary and
hypothalamus classically use a 10 mg/d E2 dose as a positive
control [22,27,50–54]. By comparing the dynamics of E2 plasma
levels in controls and animals treated with different doses of E2, we
showed that doses from 0.1 m/d tend to increase circulating E2
levels above control levels at PND1. This became statistically
significant for the 10 mg/d dose, which raised circulating levels by
up to 15 times that of the physiological levels at PND1. Thereafter,
it was not possible to maintain PND0 E2 levels by E2 injection
with a given dose because plasma E2 levels decreased from PND1
to PND3 despite repeated injections in the different treatment
ovarian samples of controls (white bars) and animals treated with 10 mg E2 at PND0 (2 h after injection) and PND1 (black bars) shows E2 impairment
of post-natal Gper up-regulation. Each bar represents mean 6 SEM of the fold-change in target gene expression relative to a Snx17 reference gene
and calibrator sample. Each point represents mRNAs from 3 to 6 pools of 6–16 and 10–26 ovaries, respectively. *p,0.05 (ANOVA, followed by PLSD
test).
doi:10.1371/journal.pone.0082175.g002
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Figure 3. Ovarian reaction to acute estrogen exposure. A. A false-color heatmap shows cases of increasing, decreasing, detectable (but
without differential expression) and undetectable transcript signal intensities across the replicates for different total ovary samples at the time points
given (top). Each line corresponds to a probe set and each column to a sample replicate. A color scale is shown for signal intensity percentiles
(bottom). Gene symbols and numbers of transcripts are shown at the right. B. Conventional RT-PCR screening of the expression of various enzymes
involved in E2 metabolism in PND0, control (C) and E2-treated (E) PND1 and adult female ovaries, and PND0 livers reveals changes in expression of
Ugt1a1, Gsta2, Gstm5 between newborn and adult ovaries, stable expression of Hsd17b2, Cyp1b1, Gstp1, and the faint expression of Sult1e1 and
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groups. This indicated that newborns progressively acquire the
capability to clear E2 form the organism. A return to levels similar
to that of controls was reached at PND6 for all dose groups but not
at PND3, ie only a few days after termination of the treatment.
The only dose where circulating levels were found to be higher
than control levels during the whole course of the treatment was
10 mg/d. Consequently, the effective dose at the systemic level is
10 mg/d. In addition, although studies on neonatal estrogen
exposure use either E2 or esters of E2 that display different half
lives in the organism [55], the effective dose is typically 1–10 mg/d
at the hypothalamus level [22,27,50–54]. By addressing dose
effects, we show here that a 10 mg/d is also the effective dose in the
ovary.
Altogether, our results on hormone profiling and mRNA
quantification after E2 injections suggest that the newborn rat
acquires the complex capability to metabolize E2 according to fine
dynamics in the days following birth. Estradiol metabolism is
carried out by enzymes that convert E2 to a biologically less active
estrogen (E1) and by phase-I and II enzymes that catalyze
oxidation and conjugations to permit their rapid excretion by the
kidney (Fig. 1A). The decrease of circulating E2 in controls
suggests that mother-derived E2 is cleared by the newborn, insofar
as the newborn itself does not synthesize E2. At birth, the rat ovary
is not able to produce E2 [56] until the granulosa cells of the first
wave of follicular growth typically express Cyp19a1. This typical
expression is associated with the peak levels of E2 during the
infantile period [5,6]. By PND2, even after repeated injections of
the highest dose, circulating E2 levels decreased concomitantly
with a sharp increase of E1. This suggests that newborn females
can convert excessive E2 into E1, which is supported by Hsd17b2
activity. Subsequent conversion of E2 and E1 into hydroxyl-
metabolites is handled by typical phase I enzymes of the Cyp
family, ie Cyp1a2, 2b1/2, 2c6, 2c11 and the 3a family [57–59].
Phase II estrogen metabolism includes sulfatation, glucuronida-
tion, O-methylation and glutathione-conjugation, which are
catalyzed by sulfo- (Sult), UDP-glucuronosyl- (Ugt), catechol-O-
methyl- (COMT) and Glutathion-S-Transferases (Gst), respective-
ly. Sulfates and glucuronides are the most abundant circulating
estrogen conjugates [60]. While glucuronides are primarily
excretion forms, sulfate derivatives have also been described as
storage forms [60,61]. The absence of statistical changes in
circulating levels of sulfated estrogens, excepted for E1S at PND3,
could reflect either the absence of increased sulfatation process
(and possibly the absence of regulation of expression and/or
activity of enzymes in charge of this process), or an increase of the
excretion of sulfate-conjugated estrogens, or both.
We were not able to measure the hydroxyl- and glucuronide-
conjugated metabolites of E2 and E1 because of their instability
and the low quantity of plasma that can be recovered in each
newborn. We therefore investigated hepatic regulation of the
mRNA expression of selected relevant enzymes of the E2
metabolic pathway. In agreement with the well-known post-natal
Cyp2b1/2 by contrast to control Snx17 RNAs. C–H. Quantitative RT-PCR for Hsd17b2 (C), Cyp1b1 (D), Cyp2b1/2 (E), Gsta2 (F), Ugt1a1 (G) and the Rbp4 E2
target gene (H) in ovaries of controls (white bars) and animals treated with 10 mg E2 (black bars) at PND0 (2 h after injection) and PND1 shows E2
impairment of post-natal Gper up-regulation. Each bar represents mean 6 SEM of the fold-change in target gene expression relative to a Snx17
reference gene and calibrator sample. Each point represents mRNAs from 3 to 6 pools of 6–16 and 10–26 ovaries, respectively. *p,0.05 (two-way
ANOVA, followed by Tukey test).
doi:10.1371/journal.pone.0082175.g003
Figure 4. Estrogen dose-dependent depletion of oocytes. A–C. Immunolabeling of TRA98 in oocytes of control animals at PND3 (A) and
females treated daily with 10 mg/d E2 between PND0 and PND2 (B). Higher magnification of TRA98 labeling shows oocyte-specific expression (C).
Scale bar = 100 mm. D–E. Stereological estimation of ovarian volume (D) and oocyte numbers per ovary (E) at PND3 in controls, and as a function of E2
dose, show a dose-dependent decrease of both parameters. Each bar represents means 6 SEM. Number of ovaries are indicated in brackets on the
abscissa. *p,0.01; **p,0.001 (ANOVA followed by Fisher test).
doi:10.1371/journal.pone.0082175.g004
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Figure 5. Characterization of oocyte depletion. A. Time-course showing the decline in oocyte number per ovary in control (white points and
dotted lines) and 10 mg E2-treated ovaries (black points and continuous lines) from PND0 to PND3. Data are expressed as mean 6 SEM of 5–14
ovaries. *p,0.01 vs. age-matched controls (ANOVA followed by PLSD test). B. Time-course of apoptotic oocyte number per ovary in control (white
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maturation of the hepatic endowment of enzymes of lipid
metabolism [7,62,63], we found up-regulation of Hsd17b2,
Cyp2b1/2 and Gsta2 and down-regulation of Cyp1b1 mRNA levels
between PND0 and 1. In contrast, transcripts encoding Ugt1a1
(which contribute to glucuronide conjugation together with
Ugt1a3, 1a8, 1a9, 1a10 and 2b7 [64,65,66]), were not modified
between PND0 and PND1. Despite its major protecting role
against E2 effects in male tissues, and the clear reproductive
phenotype in females lacking its expression [67,68], it was not
possible to investigate Sult1e1 regulation of expression as it was
expressed at levels below the qPCR threshold.
Our mRNA quantifications in the liver suggest that E2 itself, at
least at the highest dose, inhibited the physiological up-regulation
of hepatic Hsd17b2 and Cyp2b1/2 mRNA, which encode two key
enzymes of the E2 detoxification pathway. This could indicate that
the level of enzymes in the newborn liver is sufficient for E2
conversion. Alternatively, E2 treatment could counter the
physiological acquisition of the newborn liver to convert E2 into
less active metabolites. By contrast, E2 treatment had no effect on
physiological neonatal Cyp1b1 down-regulation and Gsta2 up-
regulation of expression in the liver. Cyp1b1 response to E2
exposure seems to be organ-specific since its expression is either
inducible by E2 and deoxymiroestrol (a strong phyto-estrogen in
mouse hepatocyte primary culture [69]) or down-regulated by
estrogenic compounds in peripheral organs such as rat and mouse
testis and the reproductive tract of developing female rats
[38,70,71]. This may also be the case for Gst enzymes as genistein
increases Gsta2 mRNA levels and decreases Gstp1 mRNA levels
without affecting general GST activity in adult males, and
deoxymiroestrol increases Gsta2 expression in adult mice hepato-
cyte primary culture [69,72]. Finally, hepatic Ugt1a1 mRNA levels
were not modified by E2. This would suggest that E2 treatment
has no influence on the expression of this enzyme at this age,
unlike in adult mouse livers where its expression is inducible [73].
Nevertheless, the absence of effect of E2 on Ugt1a1 and Gsta2
mRNA neonatal profiles does not preclude a modification of
expression of other Gst and Ugt, or a modification of enzyme
activity. By targeting selected enzymes of the metabolizing
pathway, E2 treatment may well favor one or more metabolic
branches over others. Collectively, our data led us to hypothesize
that by reproducing the maternal E2 environment, high levels of
E2 levels would force the liver to remain in a relative immature
state. Therefore, as suggested in the ovary, lifting the maternal E2
environment at birth could enable maturation of the newborn liver
and development of its own detoxification machinery.
Arguments in Favor of the Existence of an Ovarian Local
Metabolic Response to E2 Exposure
Neonatal estrogen exposure classically induce immediate
transcriptomic effects and long-lasting physio-pathological effects
in reproductive tissues such as the testis, ovary, uterus, oviduct and
hypothalamus, but also in other tissues including bone, kidney and
liver [74]. The search of E2 target genes is the main outcome that
is commonly investigated at the transcriptomic level. Amongst
target genes, E2 induces modifications of the detoxification
machinery in the rat adult female liver, which is the major drug-
metabolizing organ of the body [75,76], but also in reproductive
organs such as uterus, testis and fetal and juvenile ovaries
[38,77,78]. In agreement, our results suggest that local mecha-
nisms may exist in the neonatal ovary as well. Indeed, the ovary
responds to E2 exposure by modifying the expression of several E2
metabolism pathway enzymes. Although Hsd17b2 mRNA was not
thought to be expressed in the immature and mature rat ovary
[79], we found an up-regulation above basal levels in response to a
10 mg E2 injection that may increase the capability of the ovary to
transform E2 into its less active E1 metabolite [80]. On the
opposite, the PND0 to PND1 up-regulation of Cyp1b1 and
Cyp2b1/2 mRNA levels was not observed in response to a 10 mg
E2 injection, suggesting a possible decreased capability to locally
transform circulating E2 and E1 into excretable hydroxyl- and
methoxy-estrogen metabolites. We propose that, as in the liver, E2
treatment could also counter local ovarian acquisition of the
machinery involved in its own metabolism, as illustrated by a
similar inhibition of post-natal Cyp2b1/2 mRNA up-regulation.
The local ovarian mRNA up-regulation of Hsd17b2 may locally
rescue, at least in part, the absence of up-regulation in the liver.
An auto-sensory mechanism adjusting the expression of
detoxification enzymes would involve local signaling via estrogen
receptors. In agreement with previous reports in the rat [81,82],
we confirm lower expression of Esr1 in the neonatal rat ovary than
in the oviduct, expression of Esr2 in (pre-)granulosa cells which
increases with follicular growth, and low expression of Esr2 in the
cytoplasm of oocytes at birth. We also extend the knowledge of
Gper expression pattern in the rat to the neonatal period in
granulosa cells, oocytes, and surface epithelial cells of the ovary
and the oviduct, consistent with the pattern reported in the
hamster [19,83]. Altogether, the neonatal rat ovary has the
machinery to respond to E2. In contrast to other organs or
developmental periods, we were not able to show any modification
of either Esr1 or Esr2 expression associated with the 10 mg/d E2
treatment. GpermRNA, which has not been described as a classical
E2 target gene to our knowledge, did not display a physiological
increase between PND0 and PND1 in response to E2. In the
hamster, Gper was proposed to mediate E2 action on follicle
formation, as in vitro ablation with small interfering RNAs
markedly suppressed estrogen-stimulated primordial follicle for-
mation [19]. E2-disruption of post-natal Gper increase may
suggest a similar role of Gper in follicle formation in the rat. The
same trend of response to E2, albeit not statistically significant, was
found for Nr1i2 expression in agreement with mouse ovarian data).
Interestingly, the sharp increase in Nr1i2 expression in the prenatal
mouse ovary followed by a post-natal decrease at PND3, that we
also found in the rat ovary, was proposed to reflect a role for this
receptor in protecting the feto-maternal system from the toxic
effect of endogenous steroids and foreign substrates [36].
Unfortunately, Nr1i2 mRNA levels were below our in situ
hybridization detection levels so we were unable to identify the
cells that express Nr1i2. The low expression level of Nr1i2,
together with the absence of modification to its expression by E2,
reduces the likelihood of its involvement in the response to E2 high
levels.
points and dotted lines) and 10 mg E2-treated ovaries (black points and continuous lines) from PND0 to PND2. Data are expressed as mean 6 SEM of
4–8 ovaries. C–D. Quantitative RT-PCR for Bax (C), Bcl2 (D), Nobox (E), Figla (F), Scp1 (G), Hnrnpk (H), Foxo3a (I) and Eif4e (J) in ovarian samples of
controls (white bars) and animals treated with 10 mg E2 (black bars) at PND0 (2 h after injection) and PND1 shows transient down-regulation of Bcl2
mRNA at PND0 and the absence of Nobox mRNA up-regulation between PND1 and PND2 in E2-treated ovaries. Each bar represents mean 6 SEM of
the fold-change in target gene expression relative to a Snx17 reference gene and calibrator sample). Data from 3–6 pools of 6–14 ovaries. *p,0.05 vs.
age-matched control (two-way ANOVA, followed by t-test).
doi:10.1371/journal.pone.0082175.g005
Neonatal Estradiol Exposure Effects in the Rat
PLOS ONE | www.plosone.org 12 December 2013 | Volume 8 | Issue 12 | e82175
Figure 6. Abnormalities of follicle formation. A–D. Comparison of apoptosis using TUNEL (green), fibronectin (red) and nuclei (DAPI, blue) in
control (A, C) or 10 mg-E2 treated (B, D) ovaries at PND1 highlights physiological oocyte apoptosis in the areas of ovarian cords remodeling in control
ovaries, and additional oocyte apoptosis in already formed follicles in E2-treated ovaries (arrows). Insets in A–B show in situ hybridization against Ybx2
performed on the same section. C–D are higher magnifications of A–B. Scale bar: 100 mm. E–H. Comparison of oocytes labeled with Ybx2 (green) and
basement membrane labeled with fibronectin (red) and nuclei (DAPI, blue) in PND3 (E–F) and PND6 (G–H) control (E, G) and 10 mg E2-treated ovaries
(F, H) show incomplete basement membrane remodeling at PND3 in E2-treated ovaries (open arrows) and empty follicles at PND3 and PND6 (arrows).
Pictures are representative from 4–6 ovaries. Scale bar: 100 mm.
doi:10.1371/journal.pone.0082175.g006
Neonatal Estradiol Exposure Effects in the Rat
PLOS ONE | www.plosone.org 13 December 2013 | Volume 8 | Issue 12 | e82175
Estradiol and Oocyte Survival
Although the 10 mg/d E2 treatment induced a local modifica-
tion in the expression of genes encoding metabolism enzymes, we
showed that E2 exposure at the time of follicle formation induced
a dose-dependent ovotoxicity. The effect of E2 on the neonatal
ovary is often evaluated at the follicle level and previous studies
have shown that neonatal E2 exposure induces a moderate
reduction in the rate of primordial follicle assembly, a lower level
of initial primordial-to-primary follicle transition [16] and fewer
layered follicles at PND6 [84]. Similarly, neonatal exposure to
BPA reduces the pool of primordial follicles in the rat ovary [28].
Nevertheless, there may be multiple effects of E2 on follicle
assembly and/or primordial follicle activation. By focusing on the
total oocyte number, we showed a rapid effect of E2 on oocyte
survival, irrespective of the structure in which it is included.
Further studies are necessary to identify the fine mechanisms by
which E2 affects oocyte survival. However, our results contrast
with those reported in mice in which a similar range of EB doses
(0.1 to 1 mg/mouse) decrease the number of apoptotic germ cells
at PND5 [85–87]. In other in vivo studies in mice, 10 or 20 mg/
day of ethinyl estradiol did not modify whereas 100 mg/day
increased the number of oocyte per section [18,88,89], highlight-
ing the importance of the dose. In agreement, studies in hamsters
revealed that doses of E2 within the physiological range reduced
apoptosis and stimulated the formation of follicles, and that doses
above a threshold level had no effect on primordial follicle
formation but significantly up-regulated oocyte apoptosis [20]. We
show a dose-effect of E2 on oocyte depletion in the rat but no
biphasic response.
There may be several reasons for species-differences in ovarian
E2 sensitivity. Distinct estrogen receptivity at the time of follicle
assembly are unlikely because of the highly conserved expression
profiles of the different estrogen receptors, especially between these
rodent species [82,83,90]. Subtle species differences between rat
and mice have been reported in the fine mechanisms governing
the programmed cell death of oocytes at birth. Neonatal oocyte
attrition in mice involves apoptosis and autophagy mechanisms in
different cells [91], but in rats, dying oocytes can share several
features of both processes [14]. Alternatively, the xeno-estrogen
Bisphenol A was shown to hamper meiotic progression, resulting
in oocyte apoptosis in mice and humans [92,93]. This indicates
that E2 could interfere with the timing of meiosis arrest during
follicle histogenesis and ultimately induce oocyte death. Our
search for meiosis or oocyte-specific marker profiles in response to
E2 treatment showed that only Nobox expression was modified in
ovaries of E2-treated females. Indeed, Nobox mRNA did not
display the up-regulation observed between PND0-1 and PND2 in
control ovaries. This increase in controls may reflect the
expression of Nobox in oocytes of primordial and growing follicles
and thus the maturation of the organ. In E2-treated ovaries, the
absence of increased Nobox expression between PND1 and PND2
could indicate a default in the primordial-to-primary follicle
transition or a poor growth of the first wave of follicles. However,
this is countered by the absence of modification of expression in
several other oocyte-specific genes. Since mice lacking Nobox
display accelerated post-natal oocyte loss associated with a
decrease in the expression of numerous oocyte-specific genes
[44,94], the absence of increase of Nobox could involve this
pathway in the mechanism by which oocytes disappear after E2
exposure. This alternative mechanism would correlate well with
the delayed decrease in oocyte numbers between PND2 and
PND3. Nevertheless, although we were not able to detect any
changes of the number of TUNEL-positive apoptotic oocytes, or
global expression of apoptosis-related genes, we showed difference
in areas and structures where apoptotic oocytes were included.
This would suggest that E2 induces abnormal apoptosis in already
formed follicles rather than increasing physiological process.
Abnormal apoptosis of oocytes in already formed follicles
correlates well with the observation of numerous empty follicles
at PND3 and PND6. At the organ level, the number of oocytes
involved in cell death is very low; this would explain the absence of
variation of several selected oocyte markers. Further work is
needed to define the fine mechanisms of oocyte disappearance
after E2 exposure.
Estradiol and Abnormalities of Follicle Formation?
MOFs are a hallmark of several mammalian species but their
etiology is unknown [95]. Studies using E2 and E2-mimetics in
mice suggest that a decrease in oocyte apoptosis and cyst
breakdown ultimately results in MOFs [18,86]. By contrast in
the rat, massive oocyte depletion following fetal irradiation is
associated with an increased incidence of MOFs [96]. Conse-
quently, the etiology of MOFs in rat and mouse may well differ.
We show here that E2 exposure is associated with neonatal oocyte
depletion but we did not observe MOFs in older ovaries (at PND6,
PND21 and in adults, data not shown). This is in agreement with
studies in rats exposed to DES and BPA where MOFs were not
reported, or disappeared before puberty [27,28,51,84]. The timing
of oocyte depletion, between PND2 and PND3 and the presence
of apoptotic oocytes in already formed follicles at PND1 suggest
that the absence of MOFs may be explained by a depletion of
oocytes after follicle formation.
It is well established that the moment of germ cell depletion will
determine the subsequent ovarian phenotype. Irradiation-induced
fetal depletion of germ cells in the rat results in streak gonads,
whereas PND5-oocyte depletion leads to empty-primary follicles
evolving into cord-like structures where granulosa cells trans-
differentiate into Sertoli-like cells [97–99]. Neonatal exposure to
E2 in the ovaries leads to a phenotype that is more closely related
with neonatal irradiation, with a decreased oocyte pool. We here
show that neonatal E2 exposure induced oocyte depletion in
already formed follicles. Although further investigations on the fate
of pathological empty follicles are needed, we cannot exclude the
possibility that neonatal E2 exposure may also target the first wave
of follicle growth and follicle dynamics at the end of the first week.
Indeed, studies focusing on follicle dynamics in infantile rat ovaries
after neonatal E2 exposure have produced contradictory results:
some indicate that E2 increases primordial-to-primary follicle
transition in vitro and in vivo at PND8 while others report a
decrease in the number of layered follicles at PND6 [16,28,84].
However, by focusing on total oocyte numbers, our study shows
that E2 affected oocyte survival independently of the structure in
which oocytes are enclosed, in addition to its possible impact on
follicle dynamics.
Our study shows that a neonatal exposure to high E2 levels
interferes with the maturation of expression of key detoxification
tools in the liver and ovaries. In the rat ovary, E2 is ovotoxic in a
dose-dependent manner. A special care must be taken when
assigning the E2 reference dose in future studies to enable accurate
comparisons with environmental contaminants displaying estro-
genic activities.
Supporting Information
Figure S1 Expression of Esr1 in the neonatal rat ovary.
A–F. In situ hybridizations for Esr1 (A, C, E), and Esr1 sense probe
(B, D, F) in PND2 ovaries show a high level of expression of Esr1
in the epithelium of the differentiating oviduct (compare C to D),
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and in some cells of the mesenchyme of the oviduct (open arrow in
C) and a close-to-background expression in oocytes (arrows in E,
compare to F) and an expression in the ovarian surface epithelium
(E, compare with F). G Double staining of E with Ybx2 by
immunofluorescence to labeled oocytes (arrows, red). Nuclei are
counterstained with DAPI (blue). H Merged pictures of immuno-
fluorescence for Esr1 (red), Ybx2 (green) and cell nuclei (blue) in a
PND1 ovary shows a high expression of Esr1 in cells of the oviduct
mesenchyme (open arrow), an expression in epithelial cells of the
ovarian surface and follicles (arrowheads) and in oocytes (arrow).
Scale bars: 100 mm.
(TIF)
Table S1 GC-MS serum analytical control validation.
LLOQ: low limit of quantification; QC: quality control.
(DOC)
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